Neurocrine Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Neurocrine Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Neurocrine Biosciences Inc Strategy Report
- Understand Neurocrine Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Neurocrine Biosciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Neurocrine Biosciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 19 Jul 2022 | Lorem |
| LoA Update: Neurocrine’s asset for chorea in Huntington’s Disease has high approval chances after positive Phase III study | 13 Dec 2021 | William Newton |
| Neurocrine’s Phase IIb trial of Ingrezza in Tourette Syndrome raises questions around optimal dosing, given lack of published data; Phase III trial likely needed for approval, experts say | 29 Oct 2018 | Shuan Sim |
| Intra-Cellular Therapies’ lumateperone has experts largely optimistic for schizophrenia FDA approval despite one negative Phase III study | 22 Feb 2018 | Hamish McDougall |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer